

APPLICANTS: Wands et al.

FILED: Herewith

In the claims:

Cancel claims 1-22 and 26-38.

Add new claims 39-53.

APPLICANTS: Wands et al.

FILED: Herewith

39. The method of claim 23, wherein said compound is a vitamin D analogue.
40. The method of claim 23, wherein said compound is EB1089.
41. The method of claim 23, wherein said compound is Wortmannin.
42. The method of claim 23, wherein said compound blocks and IRS phosphorylation site of
SEQ ID NO:5.
43. The method of claim 23, wherein said compound binds to residues 46, 465, 551, 612,
632, 662, 732, 941, 989, or 1012 of SEQ ID NO:5.
44. The method of claim 23, wherein said tumor is selected from the group consisting of
colon cancer, breast cancer, pancreatic cancer, liver cancer, and cancer of the bile ducts.
45. The method of claim 23, wherein said tumor is a cancer of the central nervous system.
46. The method of claim 23, wherein said tumor is a hepatocellular carcinoma.
47. The method of claim 23, wherein said tumor is a cholangiocarcinoma.
48. The method of claim 23, wherein said compound is an antibody or fragment thereof.
49. The method of claim 23, wherein said compound is a dominant negative IRS mutant.
50. The method of claim 49, wherein said mutant comprises a mutation at position 897 of
SEQ ID NO:5.
51. The method of claim 49, wherein said mutant comprises a mutation at position 1180 of
SEQ ID NO:5.
52. The method of claim 23, wherein said tumor is a glioblastoma.
53. The method of claim 23, wherein said tumor is a neuroblastoma.